To explore the role and clinical therapeutic application of IL-11 in osteoarthritis

• Main Authors: KUO, CHUN-LIN, 郭俊麟
• Other Authors: Huang, Shih-Ming
• Format: Others
• Language: zh-TW
• Published: 2018
• Online Access: http://ndltd.ncl.edu.tw/handle/qwpn6j

博士 === 國防醫學院 === 醫學科學研究所 === 106 === Osteoarthritis (OA) is the most prevalent joint disease which characterized by progressive breakdown of the articular cartilage. It is known that chemokines and cytokines play a key role in the pathogenesis of OA. It has been suggested that an imbalance among pro-inflammatory and anti-inflammatory cytokines could results in accelerated inflammation in joints of patients with OA. Interleukin (IL)-11, a member of the IL-6 family of cytokines, exerts pleiotropic effects under normal and various disease conditions. We assessed IL-11 expression regulation and the IL-11/IL-6 ratio in osteoarthritis (OA) to better guide clinical therapeutic decision-making. Our findings suggest that Zac1, a zinc finger protein that regulates apoptosis and cell cycle arrest, is a transcription factor regulating IL-11 expression. Zac1 overexpression or knockdown respectively induced or suppressed IL-11 expression in HeLa cells. Zac1 acted synergistically with AP-1, human papillomavirus E2, and hypoxia inducible factor 1 alpha (HIF1α). IL-11 expression under various conditions, including hypoxia or treatment with phorbol 12-myristate 13-acetate or copper sulfate. Recombinant IL-11-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3) at tyrosine 705 was reduced in a dose-dependent manner in HeLa cells. Cross-talk between Zac1, IL-11, p53, and Suppressor of cytokine signaling 3 was differentially affected by copper sulfate, digoxin, and caffeine. Finally, aggressive vs. conventional treatment of OA patients was primarily determined by IL-6 levels. However, we suggest that OA patients with higher IL-11 levels may respond well to conventional treatments, even in the presence of high IL-6. The work will help us to understand the cross-talk between IL-6 and IL-11 and provide us a strategy to develop a new clinical guide in treatment for OA.